{"transactions":[{"id":714604,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":32031,"kind":"person","name":"Furuta Milano","position":1,"cik":"0002111400","reported_name":"Furuta Milano","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Tax Obligation Award","published_at":"2026-07-06T22:09:03.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":4288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares."}],"balance_after":4288,"derivative":{"exercise_date":"2029-06-01","expiration_date":"2029-06-01","underlying":"Ordinary Shares","underlying_shares":4288},"source":{"system":"sec-edgar","filing":"0001395064-26-000260","document":"wk-form4_1783375740.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000260/wk-form4_1783375740.xml","form_type":"4"}},{"id":714603,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":32031,"kind":"person","name":"Furuta Milano","position":1,"cik":"0002111400","reported_name":"Furuta Milano","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Tax Obligation Award","published_at":"2026-07-06T22:09:03.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":4288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares."}],"balance_after":8482,"derivative":{"exercise_date":"2028-06-01","expiration_date":"2028-06-01","underlying":"Ordinary Shares","underlying_shares":4288},"source":{"system":"sec-edgar","filing":"0001395064-26-000260","document":"wk-form4_1783375740.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000260/wk-form4_1783375740.xml","form_type":"4"}},{"id":714602,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":32031,"kind":"person","name":"Furuta Milano","position":1,"cik":"0002111400","reported_name":"Furuta Milano","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Tax Obligation Award","published_at":"2026-07-06T22:09:03.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":4288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares."}],"balance_after":11741,"derivative":{"exercise_date":"2027-06-01","expiration_date":"2027-06-01","underlying":"Ordinary Shares","underlying_shares":4288},"source":{"system":"sec-edgar","filing":"0001395064-26-000260","document":"wk-form4_1783375740.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000260/wk-form4_1783375740.xml","form_type":"4"}},{"id":714601,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":32031,"kind":"person","name":"Furuta Milano","position":1,"cik":"0002111400","reported_name":"Furuta Milano","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Tax Obligation Award","published_at":"2026-07-06T22:09:03.000Z","date":"2026-07-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16619,"price":4931.5,"value":81956598.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10."},{"field":"date","element":"transactionDate","label":"F2","text":"Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,882 to JPY 5,050, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"derivative":{"exercise_date":"2026-06-01","expiration_date":"2026-06-01","underlying":"Ordinary Shares","underlying_shares":16619},"source":{"system":"sec-edgar","filing":"0001395064-26-000260","document":"wk-form4_1783375740.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000260/wk-form4_1783375740.xml","form_type":"4"}},{"id":714600,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":32031,"kind":"person","name":"Furuta Milano","position":1,"cik":"0002111400","reported_name":"Furuta Milano","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-07-06T22:09:03.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":12300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in three equal annual installments beginning on June 1, 2027."}],"balance_after":70200,"source":{"system":"sec-edgar","filing":"0001395064-26-000260","document":"wk-form4_1783375740.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000260/wk-form4_1783375740.xml","form_type":"4"}},{"id":798715,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":32031,"kind":"person","name":"Furuta Milano","position":1,"cik":"0002111400","reported_name":"Furuta Milano","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Tax Obligation Award","published_at":"2026-04-28T10:08:00.000Z","date":"2026-04-27","kind":"grant","planned":false,"acquired":true,"shares":7814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares."}],"balance_after":16619,"derivative":{"exercise_date":"2026-06-01","expiration_date":"2026-06-01","underlying":"Ordinary Shares","underlying_shares":7814},"source":{"system":"sec-edgar","filing":"0001395064-26-000138","document":"wk-form4_1777370878.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000138/wk-form4_1777370878.xml","form_type":"4"}},{"id":798714,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":32031,"kind":"person","name":"Furuta Milano","position":1,"cik":"0002111400","reported_name":"Furuta Milano","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-04-28T10:08:00.000Z","date":"2026-04-27","kind":"grant","planned":false,"acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of ordinary shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones.  On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 27,300 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one Ordinary Share.  The RSUs vest on the following schedule: June 1, 2026 (16,200 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4000 shares)."}],"balance_after":57900,"source":{"system":"sec-edgar","filing":"0001395064-26-000138","document":"wk-form4_1777370878.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000138/wk-form4_1777370878.xml","form_type":"4"}}]}